Navigation Links
Cognitive Technologies Supports PMO for APS Healthcare
Date:11/19/2008

ted healthcare solutions that help people engage in behaviors that optimize their health status. By uniting all participants in the healthcare landscape -- individuals, practitioners and payers -- APS improves overall health and reduces total healthcare expenditures. For more information, visit http://www.apshealthcare.com.

About Cognitive Technologies

Cognitive Technologies, Inc. http://www.cognitive-technologies.com is a professional services firm that delivers technology management services and solutions to commercial and government clients. Operating at the intersection of people and technology, Cognitive Technologies specializes in project and program management, requirements, process re-design, and the implementation of PMO tools. Founded in 1987, Cognitive Technologies has offices in Washington, DC, Atlanta, GA, Hilton Head, SC, and Austin, TX. Cognitive Technologies is a Microsoft Certified Partner and a certified Microsoft Office Systems Solutions Partner.

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0904-Cognitive_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Cognitive Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Compound Tied to Cognitive Deficits in Schizophrenia
2. Cognitive Reserve May Help Fight Alzheimers
3. Springer launches Cognitive Computation
4. Cognitive Behavioral Therapy Best for Traumatized Youths
5. Breast Cancer Drug Not Tied to Cognitive Decline: Study
6. Cognitive Score Changes Over Time May Hint at Dementia
7. Rates of Mild Cognitive Impairment Higher Than Expected
8. Coronary Disease Dulls Cognitive Skills
9. Family resources, parenting quality influence childrens early cognitive development
10. Closing coal-burning power plant in China and improved cognitive development in children
11. Alcoholism-associated molecular adaptations in brain neurocognitive circuits
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6JumpStart Invests in Checkpoint Surgical 6118 1JumpStart Invests in Checkpoint Surgical 6118 2JumpStart Invests in Checkpoint Surgical 6118 3Some chest pain patients wait longer than 10 minutes to see ER physician 61033 1Some chest pain patients wait longer than 10 minutes to see ER physician 61033 2Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 1Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 2
Other Medicine Technology:Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9Video: Actress and New Mom Keri Russell Joins PKIDs to Launch 'Silence the Sounds of Pertussis' Campaign 2Video: Actress and New Mom Keri Russell Joins PKIDs to Launch 'Silence the Sounds of Pertussis' Campaign 3